Bunge stock rating reiterated at Buy by UBS on biofuel outlook

UBS reiterated its Buy rating on Bunge (BG) with a $100 price target, citing anticipated favorable regulatory outcomes by December 2025 regarding Renewable Volume Obligations and Small Refinery Exemptions, which are expected to drive strong demand for soybean oil. This outlook is bolstered by the removal of the Indirect Land Use Change penalty, enhancing soybean oil's competitiveness for biofuel. Despite a Q2 2025 revenue miss, Bunge exceeded EPS expectations and plans to raise $1.3 billion in senior unsecured notes, with JPMorgan also initiating Overweight coverage, underscoring positive analyst sentiment driven by U.S. biofuel policies.

Analysis

Bunge (BG) is receiving positive analyst coverage, with UBS reiterating a "Buy" rating ($100 PT) and JPMorgan initiating at "Overweight" ($95 PT), despite a mixed Q2 2025 performance. The company reported a significant revenue shortfall of 26.4%, with revenues of $9.17 billion against a $12.46 billion consensus, but demonstrated strong profitability by beating EPS estimates by 14.91% ($1.31 vs. $1.14). The bullish sentiment is primarily driven by future catalysts tied to U.S. biofuel policy. Bunge anticipates favorable regulatory decisions on Renewable Volume Obligations (RVO) and Small Refinery Exemptions (SRE) by December 2025. This outlook is strengthened by the removal of the Indirect Land Use Change penalty on soybean oil, improving its carbon score and competitiveness as a renewable diesel feedstock. Consequently, management expects stronger demand in 2026 and 2027. The company's strategic positioning is supported by a solid balance sheet, evidenced by a 2.07 current ratio, and a planned $1.3 billion senior notes offering to fund growth. Investors should also note the pending integration of Viterra, with updated 2025 guidance and new segment reporting expected in the third quarter, which will be a pivotal event for the company's operational and financial profile. The stock's current P/E of 8.28 suggests these potential tailwinds may not be fully reflected in its valuation.

Key Decisions for Investors

• Given the strong analyst support and a forward-looking thesis based on regulatory tailwinds in biofuels, investors could view the current P/E of 8.28 as an attractive entry point ahead of expected demand growth.
• It is crucial to monitor upcoming earnings for a reversal of the significant Q2 revenue miss, as persistent top-line weakness could challenge the positive earnings outlook and operational efficiency gains.
• Investors should closely watch for the updated 2025 guidance and re-segmentation in Q3 2025, as the successful integration of Viterra is a key variable for validating future synergies and growth.
• The forthcoming regulatory decisions on Renewable Volume Obligations and Small Refinery Exemptions by December 2025 represent a major catalyst that could significantly impact the stock's trajectory and should be monitored.